本报道最初发表于Endpoints News。请点击这里查看原文
Gilead Sciences is buying the rest of CAR-T collaborator Arcellx that it doesn’t already own, as its closely watched multiple myeloma cell therapy nears potential approval and launch.
随着备受关注的多发性骨髓瘤细胞疗法接近潜在获批与上市，吉利德科学公司(Gilead Sciences)正收购其尚未持有的CAR-T合作伙伴Arcellx的剩余股权。
您已阅读9%（297字），剩余91%（2983字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。